It appears JavaScript is disabled. In order for this website to function correctly you need to enable JavaScript in your browser.

Back to safety notices

PRAC meeting highlights 10-13 June 2024

10/06/2024

Medicines for human use Pharmacovigilance risk assessment committee (PRAC)

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.

The current PRAC highlights from the June 2024 meeting provides further information on the start of review of painkiller metamizole and risk of secondary cancers with CAR T-cell medicines.